Applied Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2017
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2017
Revenue	1	0.46	9.99	-	-	-	Upgrade
Revenue Growth (YoY)	-	-95.45%	-	-	-	-	Upgrade
Cost of Revenue	39.06	48.74	53.91	55.63	-	-	Upgrade
Gross Profit	-38.06	-48.29	-43.91	-55.63	-	-	Upgrade
Selling, General & Admin	61.56	56.01	20.62	27.32	43.05	32.68	Upgrade
Research & Development	-	-	-	-	62.57	61.79	Upgrade
Operating Expenses	61.56	56.01	20.62	27.32	105.62	94.47	Upgrade
Operating Income	-99.61	-104.3	-64.54	-82.95	-105.62	-94.47	Upgrade
Interest & Investment Income	2.09	3.53	1.37	0.69	0.56	0.56	Upgrade
Other Non Operating Income (Expenses)	78.24	-4.78	-56.57	-0.07	-	-	Upgrade
EBT Excluding Unusual Items	-19.27	-105.55	-119.74	-82.33	-105.06	-93.91	Upgrade
Gain (Loss) on Sale of Investments	-0.08	-0.08	-0.03	-0.18	-0.52	-0.05	Upgrade
Pretax Income	-18.14	-105.62	-119.76	-82.51	-105.58	-93.96	Upgrade
Net Income	-18.14	-105.62	-119.76	-82.51	-105.58	-93.96	Upgrade
Net Income to Common	-18.14	-105.62	-119.76	-82.51	-105.58	-93.96	Upgrade
Shares Outstanding (Basic)	145	140	84	38	26	22	Upgrade
Shares Outstanding (Diluted)	145	140	84	38	26	22	Upgrade
Shares Change (YoY)	10.63%	65.63%	122.72%	47.77%	16.53%	71.19%	Upgrade
EPS (Basic)	-0.13	-0.76	-1.42	-2.18	-4.12	-4.28	Upgrade
EPS (Diluted)	-0.13	-0.76	-1.42	-2.18	-4.12	-4.28	Upgrade
Operating Margin	-9961.20%	-22922.86%	-645.80%	-	-	-	Upgrade
Profit Margin	-1813.80%	-23214.07%	-1198.47%	-	-	-	Upgrade
EBITDA	-99.61	-104.3	-64.53	-82.95	-105.62	-	Upgrade
D&A For EBITDA	0	0	0	0	0	-	Upgrade
EBIT	-99.61	-104.3	-64.54	-82.95	-105.62	-94.47	Upgrade
Revenue as Reported	1	0.46	9.99	-	-	-	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.